With Over 348 Drugs In Proposed Pricing Policy, India Aims To Balance Industry Growth With Affordable Drugs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After lying in hibernation for several years, policy proposals for tighter government control on pricing of the most used medicines in India is back in the headlines as the Department of Pharmaceuticals last week posted a comprehensive draft pricing policy and called for feedback from stakeholders before Nov. 30
You may also be interested in...
India’s Price Controls To Expand To All Essential Drugs; Impact On MNCs More Severe Than Indian Firms
Long winded discussions culminated in a proposed policy framework that may impact margins of larger brands, but the industry is not yet complaining.
India May Bring 348 Drugs Under Price Control But Combinations Likely Spared
In the final stages of readying a policy framework, India may go soft on price controls
Indian Industry Lobbies Press Hard For Market-Linked Pricing Policy Framework
Industry lobbies seek to demolish several myths to avoid a policy that may potentially harm the industry and does not favour consumers either.